Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting

Summary

List prices for brand-name drugs declined in 2026, with experts attributing the decrease primarily to a Biden-era law rather than Trump administration initiatives. The article discusses pricing policy implications without identifying specific companies or drugs.